<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470405</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PHI0367</org_study_id>
    <secondary_id>VU-VICC-PHI-0367</secondary_id>
    <secondary_id>LILLY-H3E-US-S053A</secondary_id>
    <secondary_id>VU-IRB-031027</secondary_id>
    <nct_id>NCT00470405</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving pemetrexed together with oxaliplatin may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed given&#xD;
      together with oxaliplatin in treating patients with metastatic solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and the recommended phase II dose of pemetrexed&#xD;
           disodium in combination with oxaliplatin in patients with metastatic solid tumors or&#xD;
           lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxicities of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes and oxaliplatin IV over 2 hours on&#xD;
      day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of pemetrexed disodium and oxaliplatin until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, the recommended phase II dose will be identified.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days and then periodically&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>Elaxtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>a novel antifolate with multiple targets.</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic or cytologic diagnosis of solid tumors or lymphoma&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
               -  No curative or effective therapy exists&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  No clinically relevant third-space fluid collections&#xD;
&#xD;
               -  Fluid collections must be drained before study enrollment&#xD;
&#xD;
          -  No leukemia&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No active infection or other serious illness that would preclude study participation&#xD;
&#xD;
          -  No weight loss ≥ 10% within the past 6 weeks&#xD;
&#xD;
          -  No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1&#xD;
&#xD;
          -  Must be able to take concurrent vitamin B12 and folic acid&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  More than 12 months since prior adjuvant therapy&#xD;
&#xD;
          -  More than 30 days since prior drug that has not received regulatory approval&#xD;
&#xD;
          -  More than 30 days since prior radiation therapy and recovered (alopecia allowed)&#xD;
&#xD;
          -  Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed&#xD;
&#xD;
          -  No prior radiation therapy to ≥ 25% of bone marrow&#xD;
&#xD;
          -  No prior oxaliplatin or pemetrexed disodium&#xD;
&#xD;
          -  No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents [e.g.,&#xD;
             piroxicam]), during, and for 2 days after each dose of pemetrexed disodium&#xD;
&#xD;
          -  No concurrent nonpalliative radiation therapy or surgery for cancer&#xD;
&#xD;
          -  No concurrent hormonal cancer therapy (except medroxyprogesterone)&#xD;
&#xD;
          -  No other concurrent experimental medications (except thymidine)&#xD;
&#xD;
          -  No other concurrent chemotherapy or immunotherapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent palliative radiation therapy allowed for small areas of painful metastasis&#xD;
             that cannot be managed adequately by systemic or local analgesics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mace L. Rothenberg, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs. 2008 Aug;26(4):339-45. doi: 10.1007/s10637-008-9133-4. Epub 2008 May 8.</citation>
    <PMID>18463792</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mace Rothenberg</name_title>
    <organization>Vanderbilt-Ingram Cancer Center</organization>
  </responsible_party>
  <keyword>adult solid tumor</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

